drugset / Trial / NCT00667485
Rapamycin Plus Bevacizumab in Advanced Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.
Timeline
- Start
- 2008-04
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Sirolimus | Small molecule | 4 mg | Oral |
| Subject | Sirolimus | Small molecule | 6 mg | Oral |
| Subject | Sirolimus | Small molecule | 90 mg | Oral |